Halozyme Business Model Canvas

CMOs and supply chain vendors produce rHuPH20 and manage fill-finish logistics, supporting Halozyme’s Enhanze platform across more than 30 partner programs as reported in 2024. Quality-assured supply chains deliver consistency across partner programs and help enable regulatory filings and commercial launches. Scalable manufacturing capacity addresses global demand surges, while robust vendor oversight maintains compliance and continuity.

Global pharma licensees integrate ENHANZE into marketed and pipeline biologics, accelerating co-development and regulatory submissions in 2024; Enhanze supported approved products including Herceptin SC and Rituxan Hycela. Collaborations with mid-size biotechs shorten development timelines; Halozyme reported 30+ partner programs in 2024. CMOs ensure scalable rHuPH20 supply; KOLs and advocacy groups drive >70% patient SC preference data.

Regulatory strategy and filings center on preparing module components for combination submissions—CMC and clinical bridging aligned to ENHANZE co-formulation data; as of 2024 Halozyme supported more than 25 partner programs globally. Harmonizing dossiers for FDA, EMA and PMDA reduces review cycles and duplication. Rapid responses to agency queries use tailored data packages to enable efficient label updates and post-approval changes.

Continuous engineering of PEGylated rHuPH20 and formulation work optimize SC dispersion, stability and dosing; preclinical and clinical bridging inform 20+ partner programs as of 2024. ENHANZE is matched to mAbs, fusion proteins and large molecules with CMC/tech transfer and joint governance to de-risk scale-up. Regulatory support has enabled submissions across FDA, EMA and PMDA for 25+ partner programs by 2024. GMP manufacturing, vendor audits and IP prosecution sustain supply and freedom-to-operate.

Accumulated PK/PD, safety, and usability evidence from dozens of ENHANZE programs provides a robust internal dataset for comparators. Benchmark data has shortened partner development paths and reduced bridging needs, supporting faster timelines. Multiple regulatory precedents as of 2024 enable streamlined reviews, and emerging real-world outcomes strengthen payer and access discussions.

ENHANZE: 350+ issued patents/applications and trade secrets provide global protection and premium licensing leverage.

Manufacturing: validated CMC, qualified CMOs, servicing 20+ partners as of 2024 with robust QA/QC and buffer stock policies.

Data & talent: extensive PK/PD and regulatory precedents shorten partner timelines; core teams in enzyme biology, CMC, regulatory, alliances.

Leverages FDA-approved rHuPH20 (Hylenex) as a regulatory precedent to streamline approval strategies. Reduces formulation uncertainty and time-to-market by applying Enhanze know-how and validated co-formulation protocols. Provides established enzymatic assays and development guidance that improve probability of technical and regulatory success.

ENHANZE enables large-volume SC delivery cutting administration to ~5–15 min vs IV 30–120 min, preserving therapeutic exposure and improving throughput. Real-world 2024 data show 15–25% higher adherence and up to 70% lower administration costs. Flexible license/royalty/supply models align Halozyme value with partner commercialization—>20 partner programs by 2024.

Halozyme provides templates and precedent-based submission strategies aligned with FDA PDUFA timelines (priority review ~6 months; standard review ~10 months), supports protocol design and endpoints to meet regulatory expectations, commits to rapid responses to agency queries to minimize review cycles, and offers post-approval change management assistance to streamline lifecycle modifications and labeling updates.

Dedicated alliance managers and joint steering committees coordinate cross-functional work across over 60 ENHANZE programs as of 2024. Standardized tech‑transfer, SOPs and training speed regulatory/commercial readiness and support partners including Roche, Pfizer, Janssen and Eli Lilly. Shared PV, aligned med info and dashboards provide real‑time KPIs; Halozyme aligns submission strategies with FDA PDUFA timelines (~6 months priority; ~10 months standard).

Dozens of peer-reviewed publications detail PK/PD, safety, and operational benefits of Halozyme’s ENHANZE platform; as of 2024 ENHANZE enables ≥2 approved subcutaneous oncology products (Phesgo, Darzalex Faspro).

Executive outreach to pharma/biotech leverages Halozyme (NASDAQ: HALO) and Hylenex to open C‑suite channels; targeted campaigns plus portfolio reviews prioritize ENHANZE conversions (≥2 approved SC oncology products as of 2024: Phesgo, Darzalex Faspro). Conference presence (ASCO ~30,000 attendees) and relationship-driven origination accelerate deal flow. Digital partner portals cut collaboration time ~30% (2024 benchmark).

Infusion centers, hospitals and clinics using Halozyme-enabled subcutaneous therapies cut administration time from 30–90 minutes to 2–7 minutes per dose (HannaH/SC data), simplifying workflows and increasing throughput. These providers drive formulary and protocol adoption, influence payer decisions, and validate real-world value via registry and claims outcome data.

Large pharma (blockbusters > $1B) seek global, scalable SC solutions for lifecycle management. Mid-size/emerging biotechs prioritize speed-to-clinic; VC funding ~ $30B in 2024. Clinics cut admin from 30–90 min to 2–7 min with SC. Payers/HTA focus on total cost (US health spend ~$4.5T; Medicare ~65M lives).

Dossier preparation and responses demand cross‑functional teams and significant consultancy hours, driving recurring internal FTE and external‑consultant costs. Audits, inspections and QMS maintenance create steady operational spend; the FDA PDUFA fee in 2024 was about 3.2 million and routine GMP inspection/QMS budgets frequently run into the low‑hundreds of thousands annually. Pharmacovigilance operations plus regional registration fees and local consultants (EU, China, LatAm) add meaningful ongoing tail costs to Halozyme’s cost structure.

R&D/clinical per-program: assays/formulation $0.5–3M, GLP/tox $2–10M, bridging trials $1–5M per indication. Manufacturing/COGS: CMO GMP, cold-chain, process validation; platform ops $10–30M/year. Regulatory/PV: FDA PDUFA fee ~3.2M (2024); audits/QMS low‑hundreds K. Partnerships: implementation ≈10–15% of partnership spend.

Sales royalties: Halozyme secures tiered percentages on partner product net sales, commonly structured in low-single to mid-double digit ranges (2024 industry norm), rising with market penetration and additional indications. These royalties scale as partners expand label and geography, creating long-duration, annuity-like cash flows that continue over patent and contract life. Alignment with commercial success ties Halozyme upside directly to partner revenue performance, incentivizing co-commercial support and lifecycle management.

Halozyme revenue mixes upfront licensing and supply fees, milestone payments, sales royalties and option/service fees. In 2024 ENHANZE supported 60+ partnered programs and 20+ approved products, royalties typically in low-single to mid-double digit ranges, and supply/collaboration fees remained core recurring income.